Traders should monitor for actual execution of this sale, as large insider selling by a director and officer may signal lack of confidence, especially amid a pattern of sustained divestment. Consider hedging or reducing exposure ahead of potential downward price pressure.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 16 $1.88entry
- T+1 · 7mo ago 0.00%α −1.21% · $1.88
- T+5 · 7mo ago 0.00%α −0.98% · $1.88
- T+20 · 6mo ago 0.00%α −5.82% · $1.88
- T+60 · 4mo ago +376.60%α +369.55% · $8.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mark A. Goldsmith, a director and officer of Revolution Medicines, intends to sell up to 120,000 shares of common stock, valued at approximately $17.6 million, under a 10b5-1 plan. The sale is scheduled for April 15, 2026, and follows prior 10b5-1 sales by Goldsmith and affiliated trusts totaling over $4.6 million in March 2026.
Key Facts
- Mark A. Goldsmith is a director and officer of Revolution Medicines (RVMDW).
- He filed a Form 144 to sell up to 120,000 shares of common stock, valued at $17,641,200.
- The sale is scheduled for April 15, 2026, under a 10b5-1 plan.
- Goldsmith and affiliated trusts executed over $4.6 million in 10b5-1 sales in early March 2026.
- Total proposed and recent sales by Goldsmith exceed $22 million in the past month.
Financial Impact
$17.6 million in planned insider selling, part of a broader $22+ million divestment trend by the insider and related parties
Risk Factors
- Perceived lack of confidence from insider selling could negatively impact investor sentiment.
- Execution of the sale could increase market supply and contribute to downward price pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003525 |
| Document: 0001950047-26-003525-index.html | 0001950047-26-003525 |
| Document: 0001950047-26-003525.txt | 0001950047-26-003525 |
Track record
8 reports on RVMDW
The track record builds as more bullish or bearish reports settle.
Filters
- Apr 17, 202630w ago 8-K Bearish 8/10 Entry $1.88 to $9.07 ▼ −382.45% −375.67% vs SPY
- Apr 16, 202630w ago 8-K Neutral 6/10 Entry $1.88 to $8.98 ▲ +377.66% +371.52% vs SPY
- Apr 15, 202630w ago 424B5 Neutral 6/10 Entry $1.88 to $8.96 ▲ +376.60% +369.55% vs SPY
- Apr 15, 202630w ago 424B5 Bearish 7/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
- Apr 15, 202630w ago 144 Bearish 6/10 Viewing Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
- Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
- Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
- Apr 13, 202631w ago 8-K Bullish 8/10 Entry $1.88 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers